



ADALAT® ADALAT® 5 ADALAT® retard ADALAT® retard 10
Abridged Prescribing Information. Presentation: Adalat/Adalat 5: orange soft gelatin capsules containing a yellow viscous fluid, overprinted with the Bayer cross and 'ADALAT' or 'ADALAT 5' and containing 10mg or 5mg nifedipine respectively. Adalat retard/Adalat retard 10: pink-grey lacquered tablets marked with the Bayer cross and '11' or 'A10' and containing 20mg or 10mg nifedipine respectively. **Indications:** Adalat/Adalat 5: for the treatment and prophylaxis of angina pectoris and the treatment of Raynaud's Phenomenon. Adalat retard/Adalat retard 10: for the treatment of all grades of hypertension. **Dosage and Administration:** Adalat/Adalat 5: The recommended dose is one 10mg capsule three times daily with a little fluid during or after food, with subsequent titration of dose according to response. The dosage may be adjusted within the range 5mg three times daily to 20mg three times daily. Adalat 5 capsules permit titration of initial dosage in the elderly and those patients on concomitant medication. The recommended dose is one Adalat 5 capsule three times daily. Patients with hepatic dysfunction should commence therapy at 5mg three times daily with careful

monitoring. If an immediate anti-anginal effect is required, the capsule should be bitten and the liquid contents held in the mouth. Adalat retard/Adalat retard 10: The recommended dose is one 20mg tablet twice daily with a little fluid during or after food, with subsequent titration of dosage according to response. The dosage may be adjusted within the range 10mg twice daily to 40mg twice daily. Adalat retard 10 permits titration of initial dosage. The recommended dose is one Adalat retard 10 tablet twice daily and patients with hepatic dysfunction should commence therapy at this level, with careful monitoring. Regardless of the formulation used, patients with renal impairment should not require adjustment of dosage. There are no recommendations for use in children. Treatment may be continued indefinitely. **Contra-indications, warnings, etc. Contra-indications:** Nifedipine should not be administered to patients with known hypersensitivity to nifedipine or to women capable of child-bearing. Nifedipine should not be used in cardiogenic shock. **Warnings and Precautions:** Nifedipine may be used in combination with beta-blocking drugs and other antihypertensive agents but the possibility of an additive effect resulting in postural

hypotension should be borne in mind. Nifedipine will not prevent possible rebound effects after cessation of other antihypertensive therapy. Nifedipine should be used with caution in patients whose cardiac reserve is poor. Caution should be exercised in patients with severe hypotension. Ischaemic pain has been reported in a small proportion of patients within 30 minutes to four hours of the introduction of nifedipine therapy (depending on the formulation administered). Although a 'steal' effect has not been demonstrated, patients experiencing this effect should discontinue the use. The use of nifedipine in diabetic patients may require adjustment of the control. The antihypertensive effect of nifedipine may be potentiated by simultaneous administration of cimetidine. When used in combination with nifedipine, serum quinidine levels have been shown to be suppressed regardless of dosage of quinidine. No information is available on the use of nifedipine during lactation. **Side-effects:** Most side-effects are common of the vasodilator effects of nifedipine and include headache, dizziness, flushing. Gravitational oedema, not associated with heart failure or gain, has also been reported. Other less commonly reported side-

Prescribing information

Presentation Each tablet contains 2.5mg Triprolidine Hydrochloride BP and 60mg Pseudoephedrine Hydrochloride BP. Each 5ml of syrup contains 1.25mg Triprolidine Hydrochloride BP and 30mg Pseudoephedrine Hydrochloride BP. **Uses** Symptomatic relief of allergic rhinitis. **Dosage and administration** *Adults, and children over 12 years:* 1 tablet or 10ml syrup t.d.s. *Children 6-12 years:* 5ml syrup t.d.s.; *2-5 years:* 2.5ml syrup t.d.s. **Contra-indications, warnings, etc.** *Contra-indications:* Contra-indicated in patients intolerant to pseudoephedrine or triprolidine; in patients taking monoamine

oxidase inhibitors or within two weeks of stopping such treatment; and in patients with severe hypertension or severe coronary artery disease. **Precautions:** Although pseudoephedrine has virtually no pressor effect in normotensive patients, Sudafed Plus should be used with caution in patients taking anti-hypertensive agents, tricyclic antidepressants, or other sympathomimetic agents. Because of its pseudoephedrine content, Sudafed Plus may partially reverse the effect of anti-hypertensive agents which modify sympathetic activity. **Side- and adverse effects:** In some patients, pseudoephedrine may occasionally cause insomnia. Rarely, sleep disturbances and

hallucinations have been reported. Triprolidine may cause drowsiness, and patients should not drive a vehicle or operate machinery until they have determined their own response. In some patients, the drowsiness induced by antihistamines may be potentiated by alcohol or other central sedatives. **Basic NHS costs** Tablets: £0.65 for 10 (PL3/0248). Syrup: £1.06 for 100ml (PL3/0247). Further information is available on request. **Calmic Medical Division**
The Wellcome Foundation Ltd,
Crewe, Cheshire



Blocked-up?



Clear blocked noses with
dual-action Sudafed Plus.

Decongestant plus antihistamine for allergic rhinitis.

SUDAFED*

Pseudoephedrine Hydrochloride BP
Triprolidine Hydrochloride BP

*Trade Mark

**CALMIC MEDICAL
DIVISION**

THE WELLCOME FOUNDATION LTD